A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy

Table 4 Comparison of baseline characteristics between the two groups of treatment outcome^a

Variable, Total (n = 57 orbits)	Favorable	Unfavorable
n, (%)	(29)	(28)	p-value
Age ≥ 55 years	13 (44.8)	19 (67.9)	0.08
Female sex	22 (75.9)	25 (89.3)	0.297^†
Smoking	11 (37.9)	8 (28.6)	0.454
Poor baseline visual acuity	26 (89.7)	19 (67.9)	0.44
Disc swelling	11 (37.9)	7 (25)	0.294
Proptosis	11 (37.9)	21 (75)	*0.005*
Euthyroid status	13 (44.8)	11 (39.3)	0.672
Type 2 diabetic mellitus	8 (27.6)	14 (50)	0.082
Duration of vision loss ≥1 month.	15 (51.7)	18 (64.3)	0.337

^a The favorable outcome criteria are considered ≥0.2 improved in logMAR after 1 week of IVMP. Prognosis-related factors were selected based on a review of the literature. Percentages may not total 100 because of rounding-off. Cut-off for poor baseline visual acuity is logMAR of ≥1. IVMP Intravenous methylprednisolone. logMAR Logarithm of the minimum angle of resolution. Bold italicized text indicates statistical significance
† Fisher’s exact test

ISSN: 1471-2415